Friday, 15 Feb 2019

You are here

Predictors of Methotrexate Non-Response

Methotrexate (MTX) is the first line disease-modifying antirheumatic drug (DMARD) used for the treatment of rheumatoid arthritis (RA) as it is the most cost effective first drug, monotherapy drug and the anchor drug upon which most successful combination drug regimens are built around.  As success of this agent is critical to ultimate outcomes, predicting success would be an incredible advantage.

New research from a UK study suggests that nonresponse to oral or subcutaneous MTX was seen in 43% and is predicted by seronegativity, higher disease activity measures and higher anxiety scores.

The Rheumatoid Arthritis Medication Study (RAMS) is a UK multi-centre prospective observational study of patients with RA or undifferentiated polyarthritis, who are started on first line MTX therapy.  MTX non-response at 6 months was based on EULAR response criteria, discontinuation of MTX due to inefficacy or need to start a biologic agent. 

Among 1050 enrolled patients, 43% were classified as non-responders.

Independent predictors of MTX non-response were rheumatoid factor (RF) negativity (OR = 0.62 (0.45, 0.86), higher Health Assessment Questionnaire score (OR=1.64 (1.25, 2.15)), higher tender joint counts (OR=1.06 (1.02, 1.10)), higher anxiety scores (OR=1.07 (1.03, 1.12)) and lower DAS28 scores (OR=0.29 (0.23, 0.39)).

The surprising association with a lower DAS28 score is best explained byt  the method (EULAR) used to calculate a non-response. Thus, patients with a low baseline DAS28 were unable to drop their score by the requisit 0.6 and thus have less of a chance to achieve a response. The AUC for this model was 0.74.

Other sensitivity analyses looked at failing to achieve low disease activity after 6 months of MTX. This was predicted by higher BMI, higher HAQ score, higher TJC28 and higher anxiety score, but not a lower baseline DAS28.

This study is notable by its large size, higher than expected non-response rate (due to dosing?) and the identification of anxiety as a predictive variable in clinical outcome. It is possible that baseline anxiety could be addressed at the start of therapy. 

The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

No Difference in Oral or IV Antibiotics for Bone & Joint Infections

Research from the NEJM shows that oral antibiotic therapy was noninferior to intravenous antibiotic therapy when used during the first six weeks for complex orthopedic infections.

There is considerable discussion whether complex bone and joint infections must be managed with prolonged intravenous antibiotics or if oral antibiotic therapy may suffice. 

2019: the Year of Price Hikes

In 2019 there have been numerous reports of higher drug pricing for many drugs.  Yesterday it was reported that the price of insulin drugs have more than doubled from 2012 to 2016.

Reuters reports that in the United States, the pricing on more than 250 prescription drugs have gone up.

Does Methotrexate Work in Giant Cell Arteritis?

There seems to be both hope and uncertainty regarding the use of weekly methotrexate (MTX) in giant cell arteritis (GCA) patients whom need to limit their glucocorticoid use. While well done clinical trials have shown no certain efficacy, data suggesting MTX benefits comes from small trials, anecdotes and clinical experience. 

Price of Drug Promotion Skyrockets

JAMA reports that health care advertising costs in the U.S. have almost doubled over the past two decades, surging from $17.7 billion in 1997 to at least $29.9 billion in 2016. (Citation source:

2018 Rheumatology Year In Review

This annual appraisal of hallmark moments, news and research articles from 2018 are gleaned from that published in RheumNow during the last year and filtered by other news sources and literature review.  The top 10 list herein is rooted in what rheumatologists should know and what will likely change their standards and practice in the future, if not 2019.